The webinar took place earlier this month and featured two new studies using WWARN-hosted clinical trial data showing that the dosing of the 8-aminoquinolin drugs primaquine and tafenoquine can be substantially improved. These analyses include the majority of all studied vivax malaria patients who received 8-aminoquinoline drugs over the last 20 years. Laboratory work confirms these findings and provides important new information on the mechanism of action of these essential medicines.
- Dr Rob Commons, Menzies School of Health Research, on 8AQ efficacy in clinical trials
- Dr Alison Roth, Walter Reed Army Institute of Research, on laboratory studies assessing hypnozoitocidal activity
- Dr James Watson, Oxford University Clinical Research Unit, on the reassessment of tafenoquine pharmacometrics
Videos of the three webinar presentations are available on our TropMed Webinars page
Read the publication 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis' on the elife website
The full story is available on the IDDO website